linjc16/ctgov huggingface dataset:
Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT

Study Overview
=================
Brief Summary
-----------------
The build up of plaque in the wall of the artery supplying blood to the brain poses a risk of stroke when the plaques become unstable and fragile. It is important to determine which patients are most at risk so that surgery can be performed. There is evidence that the risk is greatest when these plaques become oxygen deficient (hypoxic). The investigators wish to use PET imaging to identify hypoxic plaque, to help decide whether and when to perform surgery. The investigators have developed radiotracers (imaging agents) for this purpose, and this study is to determine whether they will work in patients.

Official Title
-----------------
A Mechanistic, Non-randomised Study to Examine the Uptake of a Specific Radionuclide (61CuATSM) in Carotid Artery Plaque

Conditions
-----------------
Carotid Atherosclerosis

Intervention / Treatment
-----------------
* Other: PET-CT with CuATSM


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male/Female patients who are 55yrs or older and for whom carotid endarterectomy is clinically indicated and a decision has been made to perform a carotid endarterectomy. Normal liver and adequate renal function. Assessed by measuring eGFR (>50ml/min) and creatinine (<130μmol/L) Life expectancy > 12 weeks Patients should be able to tolerate head/neck mask as well as lying in the PET-CT scanner Exclusion Criteria: Abnormal liver and renal function (eGFR <50ml/min, Creatinine >130μmol/L) Patient unwilling to provide written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing carotid endarterectomy<br> | Other: PET-CT with CuATSM<br>* PET-CT with CuATSM<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uptake of CuATSM in carotid plaque |  | Within 30 days of carotid endarterectomy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship of CuATSM uptake to plaque histology |  | Within 30 days of carotid endarterectomy |
Symbicort SMART (Symbicort Maintenance And Reliever Therapy)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.

Official Title
-----------------
SMART (Symbicort Maintenance And Reliever Therapy): Reassure Program for Patients Using Symbicort Turbuhaler as Maintenance and Reliever Therapy in Korean Clinical Practice

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this program. Exclusion Criteria: Since this programme intends to describe Symbicort use in routine clinical practice when prescribed as Symbicort maintenance and reliever therapy, there are no programme specific exclusion criteria, other than: involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Symbicort, SMART, inhaler, compliance, Naturalistic, Observational
Ultrasonic Measurement of IVC and IJV in Predicting Hypotension After Anesthesia Induction

Study Overview
=================
Brief Summary
-----------------
This research is expected to study ultrasonic measurement of internal jugular vein and inferior vena cava, which can be used as a good index to predict hypotension after anesthesia induction, and its measurement method is simple and quick.

Detailed Description
-----------------
The induction of anesthesia is the process from the physiological state to the anesthetic state in a short period of time. Hypotension after anesthesia induction is closely related to many organ injuries. Gastrointestinal surgery patients' prohibition of fasting is an important mechanism of severe hypotension after anesthesia induction. At present, ultrasonic measurement of inferior vena cava and internal jugular vein has been proved to be a convenient and non-invasive means to evaluate patients' blood volume. The purpose of this research was to study the relativity between ultrasonic measurement of inferior vena cava and internal jugular vein and hypotension after anesthesia induction in patients.

Official Title
-----------------
Ultrasonic Measurement of Inferior Vena Cava and Internal Jugular Vein in Predicting Hypotension After Anesthesia Induction in Patients Undergoing Gastrointestinal Surgery

Conditions
-----------------
Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastrointestinal surgery BMI 18 24 ASA score gradeⅠ  III Exclusion Criteria: anemia cirrhosis Emergency surgery severe hypertension New York Heart Association III   IV or ejection fraction <40% cirrhosis Other serious systemic diseases

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hypotension<br>Patients with hypotension after induction of anesthesia | |
| non-hypotension<br>Patients without hypotension after induction of anesthesia | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of hypotension after anesthesia Induction | Hypotension can be diagnosed if one of the following conditions is true: (1) a decrease in mean arterial pressure of > 20% compared to the baseline value (2) mean arterial pressure < 60mmHg | within 12 hours after anesthesia induction | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ultrasonic measurement of inferior vena cava and internal jugular vein | Measure the maximum diameter, minimum diameter and cross-sectional area of inferior vena cava and internal jugular vein | within 1 hour before anesthesia induction |
Take-Care Program: Effectiveness of a Physical Therapy Program on Cancer Related Symptoms

Study Overview
=================
Brief Summary
-----------------
Effectiveness of a physical therapy program focussed on core stability exercise and massage as a recovery method in breast cancer survivors after oncology treatment.

Detailed Description
-----------------
Eligibility Criteria 1, had a diagnosis of breast cancer (stage I-IIIA); 2, between 25-65 years; 3, finished co-adjuvant treatment except hormone-therapy; 4, not having active cancer; 5, interest to improve their lifestyle increasing physical activity; and, 6, present 3 to 5 of the following physical findings, judged by the oncologist who referred the patient: neck or shoulder pain symptoms, reduced range of motion in neck- shoulder area, reduced physical capacity, any psychological problem, increased fatigue, sleep disturbances, or any problem in coping with reduced physical and psychosocial functioning. Principal Outcomes Fatigue Score: Piper Fatigue Scale Mood State:Profile of Mood State Quality of Life: QLQ-BR23

Official Title
-----------------
TAKE-CARE: EFFECTIVENESS OF A PHYSICAL THERAPY COMBINING CORE STABILITY EXERCISE AND MASSAGE IN CANCER RELATED SYMPTOMS

Conditions
-----------------
Breast Cancer

Intervention / Treatment
-----------------
* Other: Physical Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Finished oncology treatment (chemotherapy, radiation, surgery) Exclusion Criteria: Other musculoskeletal conditions.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Usual care<br> | |
| Experimental: Physical therapy<br> | Other: Physical Therapy<br>* Core Stability Exercise, Endurance training, recovery massage<br>* Other names: Recovery techniques;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in Fatigue Related Cancer at 6 months | Piper Fatigue Scale | Baseline, 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline in strength at 6 months | Leg strength, core muscles strength, arm strength | Baseline, six months | 
| Change from Baseline in Quality of Life at 6 months | QLQ-Br23 | Baseline, six months | 
| Change from Baseline in profile of mood state at 6 months | Profile of Mood State | Baseline, six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
massage, breast cancer, physical therapy, core stability
Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.

Study Overview
=================
Brief Summary
-----------------
Prospective randomized controlled clinical trials (single arm study) of surgical treatment modalities for supratentorial high grade gliomas within the next two years.

Detailed Description
-----------------
Supratentorial high grade gliomas are for surgical resection in any case according to many factors. Investigators will compare the outcomes/survival rate and clinical outcome of the different resection types (Total, near total, subtotal/debulking) of supratentorial high grade gliomas according to the clinical condition and comorbidities of the patient, the location and morphology of the lesion, the grading of lesions, and the clinical experience of the neurosurgeon.

Official Title
-----------------
Prognostic Impact of Surgical Resection Extent for Supratentorial High Grade Gliomas.

Conditions
-----------------
Supratentorial Glioblastoma

Intervention / Treatment
-----------------
* Procedure: Supratentorial high grade gliomas resection.


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who will undergo surgical excision of the supratentorial high grade gliomas at the time of study (two years). Denovo disease for the first time. Any age Exclusion Criteria: Low-grade Gliomas. Infratentorial high-grade gliomas. Past history of gliomas. Patients who are unfit for any neurosurgical interventions. Patients who do not receive their adjuvant standard therapy.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Supratentorial high grade gliomas resection.|Total, near total or subtotal/debulking resection of the brain supratentorial high grade gliomas|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical picture using Modified Rankin's Scale (mRS). | The changes in clinical condition of the patients will be assessed using Modified Rankin's Scale (mRS) before and after treatment. The scale runs from 0-6, running from perfect health without symptoms to death. 0 - No symptoms. - No significant disability. Able to carry out all usual activities, despite some symptoms. - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. - Moderate disability. Requires some help, but able to walk unassisted. - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. - Dead. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence or increased residual | Recurrence of the tumor | within 3 months after treatment |
Reducing Intracranial atheroSclErosis With Repatha

Study Overview
=================
Brief Summary
-----------------
The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing atherosclerotic plaque, which would be particularly beneficial for patients with intracranial atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.

Official Title
-----------------
Reducing Intracranial atheroSclErosis With Repatha

Conditions
-----------------
Ischemic Stroke

Intervention / Treatment
-----------------
* Drug: Repatha


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients, ≥ 18 years of age History of ischemic stroke, defined as an episode of neurological dysfunction caused by focal cerebral, spinal, or retinal infarction (American Heart Association definition). Large vessel atherosclerosis of an intracranial artery in the circle of Willis with 50-99% stenosis by WASID criteria (percent stenosis = (1-[diameter stenosis/diameter normal]) x 100%) on MRA, CTA or DSA ------ Eligible arteries: vertebral (V4), basilar, PCA (P1, P2), MCA (M1, M2), tICA, ACA (A1) Current statin use or contraindication to statin Fasting LDL-C ≥ 70 mg/dL or LDL-C ≥ 60 mg/dL if lipoprotein (a) > 30 mg/ dL Exclusion Criteria: Gadolinium or PCSK9 inhibitor allergy Acute or chronic kidney disease with eGFR<30 ml/min/1.73m2 Pacemaker or other MRI contraindications per American College of Radiology guidelines Inability to return for 78 week follow-up clinic visit and vwMRI

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Intervention Repatha<br> | Drug: Repatha<br>* 140 MG in 1 ML Prefilled Syringe PCSK9 Inhibitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stenosis | Measured on ToF MRA, CE-MRA, T1 Dante | 1.5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Atheroma Volume | Measured on ToF MRA, CE-MRA, T1/T2/PD Dante | 1.5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial Atherosclerosis
Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study

Study Overview
=================
Brief Summary
-----------------
online questionnaire will be distributed in different country to detect the oral change in patient diagnosed with COVID-19

Detailed Description
-----------------
an online survey will be performed through google form. Investigators in different country will share the questionnaire with patient diagnosed positive COVID-19. data collected will be statically analyse to detect the oral picture of the virus.

Official Title
-----------------
Oral Manifestations of COVID-19: a Multicentre Observational Study

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: positive COVID-19 Exclusion Criteria: children patient not confirmed by swab

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| positive COVID-19<br>patient diagnosed by nasopharyngeal positive COVID-19 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oral ulcer | number of patient with oral ulcer | through study completion, an average of 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| hyposalivation | change in salivary flow | through study completion, an average of 1 month |
The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock

Study Overview
=================
Brief Summary
-----------------
To explore the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis/septic shock;To compare the PK/PD of deoxycholic amphotericin B in invasive fungal infection patients with sepsis and septic shock.

Detailed Description
-----------------
This was a single-center study.Patients who were diagnosed with in invasive fungal infection receieved deoxycholic acid amphotericin B during the study period.The information was recored including the general condition, infection index, PK/PD index and drug-related side effects.

Official Title
-----------------
The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock

Conditions
-----------------
Fungal Infection

Intervention / Treatment
-----------------
* Drug: Deoxycholic acid amphotericin B


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients age more than 18 years old; Meet the criteria of Sepsis 3.0; Admitted to ICU; Patients were suspected or diagnosis of IFI,doctors determined the use of deoxycholic acid amphotericin B. Exclusion Criteria: Serum creatinine≥221umol/L; Deoxycholic acid amphotericin B or amphotericin B liposome were used for the past 7 days; Patients being treated with rifampicin; Unable to tolerate treatment of deoxycholic acid amphotericin B; BMI<18.5 or >30; Tumors; Pregnancy; Estimated time of survival<24h; Patients who participated in other studies within 30 days.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| sepsis group<br>invasive fungal infection patients who were diagnosed sepsis accoreding to the sepsis 3.0 guidlines. | Drug: Deoxycholic acid amphotericin B<br>* Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.<br>* Other names: amphotericin B;|
| septic shock group<br>invasive fungal infection patients who were diagnosed septic shock accoreding to the sepsis 3.0 guidlines. | Drug: Deoxycholic acid amphotericin B<br>* Starting with 1mg and increasing by 5-25mg daily until the maintenance dose is 50mg/d.<br>* Other names: amphotericin B;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cmax/MIC | PK/PD of Deoxycholic Acid Amphotericin B | 14 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AUC24h/MIC | Concentration of Deoxycholic Acid Amphotericin B | 14 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Blood Concentration, Deoxycholic Acid Amphotericin B, Fungal Infection
A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System

Study Overview
=================
Brief Summary
-----------------
This study is a prospective, multi-center registry of patients with intracranial aneurysms who are treated by the PC 400 System. Data for each patient are collected up to 12 ± 3 months post-procedure for the study.

Official Title
-----------------
VOLCAN: A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System

Conditions
-----------------
Intracranial Aneurysms

Intervention / Treatment
-----------------
* Device: PC 400 coils


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years Intracranial aneurysms >2mm, ruptured or unruptured Exclusion Criteria: Fusiform aneurysms Dissecting aneurysms Aneurysms associated with brain AVMs Multiple aneurysms Re-treated aneurysms Patients in whom endovascular embolization therapies other than PC 400 System are used will be excluded from this study. However, adjunctive use of balloon and stent are acceptable.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment by the PC 400 coils<br>Patients enrolled in this study must be those treated according to the cleared indication for the PC 400 System in the Instructions for Use. | Device: PC 400 coils<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Packing density with the number of coils implanted |  | During the procedure | 
| Time of fluoroscopic exposure |  | During the procedure | 
| Procedural device-related serious adverse events at immediate post-procedure |  | During the procedure | 
| Quality of aneurysm occlusion post-operatively and at 12±3 months post-procedure based on the Raymond Scale |  | At 1 year post-procedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute occlusion of the aneurysm sac at immediate post-procedure |  | At immediate post-procedure | 
| Adverse events occurring during the procedure and in the 30±7 days following the treatment. |  | During and at 30 days post-procedure |